{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:26:33Z","timestamp":1785900393323,"version":"3.56.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010890","name":"Oxford Nanopore Technologies plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmdjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jmoldx.2026.03.003","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:58:58Z","timestamp":1774630738000},"page":"485-492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Performance Evaluation of a PCR\/Nanopore Assay for Carrier Screening for Cystic Fibrosis, Spinal Muscular Atrophy, and Fragile X Syndrome"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6563-9855","authenticated-orcid":false,"given":"Kendall E.","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"S\u00e1bato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ferreira-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1146-5001","authenticated-orcid":false,"given":"Elizabeth S.","family":"Barrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2026.03.003_bib1","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41436-021-01203-z","article-title":"Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"23","author":"Gregg","year":"2021","journal-title":"Genet Med"},{"key":"10.1016\/j.jmoldx.2026.03.003_bib2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/AOG.0000000000001947","article-title":"Committee opinion no. 690 summary: carrier screening in the age of genomic medicine","volume":"129","year":"2017","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jmoldx.2026.03.003_bib3","first-page":"1","article-title":"Carrier screening programs for cystic fibrosis, fragile X syndrome, hemoglobinopathies and thalassemia, and spinal muscular atrophy: a health technology assessment","volume":"23","year":"2023","journal-title":"Ont Health Technol Assess Ser"},{"key":"10.1016\/j.jmoldx.2026.03.003_bib4","article-title":"Updated recommendations for CFTR carrier screening: a position statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"25","author":"Deignan","year":"2023","journal-title":"Genet Med"},{"key":"10.1016\/j.jmoldx.2026.03.003_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/TACG.S239603","article-title":"Spinal muscular atrophy: mutations, testing, and clinical relevance","volume":"14","author":"Keinath","year":"2021","journal-title":"Appl Clin Genet"},{"key":"10.1016\/j.jmoldx.2026.03.003_bib6","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1038\/s41431-018-0193-4","article-title":"Utility of two SMN1 variants to improve spinal muscular atrophy carrier diagnosis and genetic counselling","volume":"26","author":"Al\u00edas","year":"2018","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.jmoldx.2026.03.003_bib7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/gim.2013.84","article-title":"An Ashkenazi Jewish SMN1 haplotype specific to duplication alleles improves pan-ethnic carrier screening for spinal muscular atrophy","volume":"16","author":"Luo","year":"2014","journal-title":"Genet Med"},{"key":"10.1016\/j.jmoldx.2026.03.003_bib8","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/gim.2012.34","article-title":"AGG interruptions within the maternal FMR1 gene reduce the risk of offspring with fragile X syndrome","volume":"14","author":"Yrigollen","year":"2012","journal-title":"Genet Med"},{"key":"10.1016\/j.jmoldx.2026.03.003_bib9","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/jama.291.4.460","article-title":"Penetrance of the fragile X-associated tremor\/ataxia syndrome in a premutation carrier population","volume":"291","author":"Jacquemont","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jmoldx.2026.03.003_bib10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1212\/WNL.57.1.127","article-title":"Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X","volume":"57","author":"Hagerman","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.jmoldx.2026.03.003_bib11","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/(SICI)1096-8628(19990402)83:4<322::AID-AJMG17>3.0.CO;2-B","article-title":"Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X Study\u2014Preliminary data","volume":"83","author":"Allingham-Hawkins","year":"1999","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.jmoldx.2026.03.003_bib12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/ajmg.1320510444","article-title":"Mosaicism in fragile X affected males","volume":"51","author":"Nolin","year":"1994","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.jmoldx.2026.03.003_bib13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s13059-016-1103-0","article-title":"The Oxford Nanopore MinION: delivery of nanopore sequencing to the genomics community","volume":"17","author":"Jain","year":"2016","journal-title":"Genome Biol"},{"key":"10.1016\/j.jmoldx.2026.03.003_bib14","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s12967-025-06345-1","article-title":"Targeted long-read sequencing facilitates effective carrier screening for complex monogenic diseases including spinal muscular atrophy, [alpha]-\/[beta]-thalassemia, 21-hydroxylase deficiency, and fragile-X syndrome","volume":"23","author":"Li","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.jmoldx.2026.03.003_bib15","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jmoldx.2025.03.008","article-title":"Fragile X syndrome carrier screening using a nanopore sequencing assay","volume":"27","author":"Xia","year":"2025","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2026.03.003_bib16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s40246-024-00676-8","article-title":"Evaluating the clinical efficacy of a long-read sequencing-based approach for carrier screening of spinal muscular atrophy","volume":"18","author":"Long","year":"2024","journal-title":"Hum Genomics"},{"key":"10.1016\/j.jmoldx.2026.03.003_bib17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/ng0293-151","article-title":"Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA","volume":"3","author":"Chu","year":"1993","journal-title":"Nat Genet"},{"key":"10.1016\/j.jmoldx.2026.03.003_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/srep38776","article-title":"Intragenic CFTR duplication and 5T\/12TG variant in a patient with non-classic cystic fibrosis","volume":"6","author":"Celestino-Soper","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jmoldx.2026.03.003_bib19","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jcf.2022.04.020","article-title":"Clinical outcomes of a large cohort of individuals with the F508del\/5T;TG12 CFTR genotype","volume":"21","author":"Tosco","year":"2022","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jmoldx.2026.03.003_bib20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2353\/jmoldx.2008.070105","article-title":"Consensus characterization of 16 FMR1 reference materials: a consortium study","volume":"10","author":"Wilson","year":"2008","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2026.03.003_bib21","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/GIM.0b013e31818e55a2","article-title":"Clinical practice and genetic counseling for cystic fibrosis and CFTR-Related disorders","volume":"10","author":"Moskowitz","year":"2008","journal-title":"Genet Med"},{"key":"10.1016\/j.jmoldx.2026.03.003_bib22","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/humu.24250","article-title":"Elucidating clinical phenotypic variability associated with the polyT tract and TG repeats in CFTR","volume":"42","author":"Nykamp","year":"2021","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jmoldx.2026.03.003_bib23","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.3390\/genes13091657","article-title":"Recommendations for interpreting and reporting silent carrier and disease-modifying variants in SMA testing workflows","volume":"13","author":"Milligan","year":"2022","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.jmoldx.2026.03.003_bib24","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/jmg.2009.066969","article-title":"Differences in SMN1 allele frequencies among ethnic groups within North America","volume":"46","author":"Hendrickson","year":"2009","journal-title":"J Med Genet"},{"key":"10.1016\/j.jmoldx.2026.03.003_bib25","article-title":"Amplification-free, CRISPR-Cas9 targeted enrichment and SMRT sequencing of repeat-expansion disease causative genomic regions","author":"Tsai","year":"2017","journal-title":"BioRxiv"},{"key":"10.1016\/j.jmoldx.2026.03.003_bib26","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/clinchem\/hvac154","article-title":"Comprehensive analysis of fragile X syndrome: full characterization of the FMR1 locus by long-read sequencing","volume":"68","author":"Liang","year":"2022","journal-title":"Clin Chem"},{"key":"10.1016\/j.jmoldx.2026.03.003_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.743230","article-title":"Characterization of FMR1 repeat expansion and intragenic variants by indirect sequence capture","volume":"12","author":"Grosso","year":"2021","journal-title":"Front Genet"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157826000449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157826000449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T19:44:48Z","timestamp":1779997488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157826000449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1525157826000449"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2026.03.003","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Performance Evaluation of a PCR\/Nanopore Assay for Carrier Screening for Cystic Fibrosis, Spinal Muscular Atrophy, and Fragile X Syndrome","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmoldx.2026.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}